CRWD vs MRK: Which Is the Better Buy?
Side-by-side comparison of CrowdStrike Holdings, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-09.
CrowdStrike Holdings, Inc. · Technology
$191.12
+32.7% upside to fair value
Grade B
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
CRWD has more upside to fair value
(+32.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWD |
MRK |
| Current Price |
$191.12 |
$113.87 |
| Fair Value Estimate |
$253.64 |
$100.14 |
| Upside to Fair Value |
+32.7%
|
-12.1%
|
| Market Cap |
$194.6B |
$281.2B |
| Forward P/E |
-4023.6x
|
32.0x
|
| EV / EBITDA |
570.3x
|
17.3x
|
| Price / Sales |
38.2x
|
4.3x
|
| Price / FCF |
134.0x
|
19.9x
|
| Revenue Growth YoY |
+25.6%
|
+4.3%
|
| Gross Margin |
75.0%
|
75.9%
|
| Operating Margin |
-3.9%
|
27.6%
|
| Return on Equity |
-0.6%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
0.75%
|
5.02%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
CrowdStrike Holdings, Inc. operates in the technology sector, specifically in software infrastructure, providing cybersecurity solutions. The business quality is medium due to its strong revenue growth of 25.6% in the most recent quarter and impressive earnings growth of 125.2% in the same period, indicating effective scaling and operational leverage. However, profitability metrics remain challen…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
CRWD |
MRK |
| Zone Low |
$190.23 |
$75.11 |
| Zone High |
$215.59 |
$85.12 |
| In Buy Zone? |
Yes
|
No
|